Tracy Porter - Taysha Gene Chief Officer
| TSHA Stock | USD 3.24 0.24 8.00% |
Insider
Tracy Porter is Chief Officer of Taysha Gene Therapies
| Address | 3000 Pegasus Park Drive, Dallas, TX, United States, 75247 |
| Phone | 214 612 0000 |
| Web | https://www.tayshagtx.com |
Taysha Gene Management Efficiency
The company has return on total asset (ROA) of (0.2742) % which means that it has lost $0.2742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1477) %, meaning that it created substantial loss on money invested by shareholders. Taysha Gene's management efficiency ratios could be used to measure how well Taysha Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.68. The current year's Return On Capital Employed is expected to grow to -0.51. At present, Taysha Gene's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 25.2 M, whereas Total Assets are forecasted to decline to about 169.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Neelesh MD | Prelude Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Erin JD | Shattuck Labs | 44 | |
| FACR MD | Cabaletta Bio | 59 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Casi DeYoung | Shattuck Labs | 53 | |
| Prof MD | Hookipa Pharma | 80 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Franco Valle | Biomea Fusion | 43 | |
| Conor Richardson | Shattuck Labs | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 |
Taysha Gene Therapies Leadership Team
Elected by the shareholders, the Taysha Gene's board of directors comprises two types of representatives: Taysha Gene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taysha. The board's role is to monitor Taysha Gene's management team and ensure that shareholders' interests are well served. Taysha Gene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taysha Gene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Greg Gara, VP Manufacturing | ||
| Tracy Porter, Chief Officer | ||
| Hayleigh Collins, Director Communications | ||
| Jim Rouse, Chief Officer | ||
| R II, President, Founder | ||
| FFPM MSc, Chief RD | ||
| Steven Gray, Chief Program | ||
| Berge MD, Chief Program | ||
| Frederick Porter, Chief Officer | ||
| Mishima Gerhart, Chief Quality | ||
| Emily MPH, Chief Affairs | ||
| Sean McAuliffe, Chief Officer | ||
| Sukumar MD, Head President | ||
| Rumana HaqueAhmed, Chief Officer | ||
| Sean Nolan, CEO Chairman | ||
| Tracy SPHR, Chief Officer |
Taysha Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Taysha Gene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 568.87 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 77.45 % | ||||
| Number Of Shares Shorted | 15.75 M | ||||
| Price To Book | 7.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.